

LISTING OF THE CLAIMS:

1. (Currently Amended) A ~~pharmaceutical~~ unit dosage form tablet or capsule
composition for oral administration comprising
 - a) a an enteric coated magnesium component having an active ingredient
consisting essentially of one or more magnesium compounds, wherein said enteric coating is
a polymeric and a release-controlling agent which substantially prevents release of said one
or more magnesium compounds until passage out of the stomach and into the intestine of the
host, and wherein said release-controlling agent has a pH dissolution point of from about 5 to
about 8; and
 - b) a an uncoated calcium component having an active ingredient consisting
essentially of one or more calcium compounds;

wherein substantially all of said calcium component is released before passage into
said intestine of said host, and wherein the ratio of said calcium component to said
magnesium component is from 1:5 to 5:1.
2. (Canceled) A ~~pharmaceutical composition according to Claim 1, wherein~~
~~said release-controlling agent is an enteric coating having a pH dissolution point of from~~
~~about 5 to about 8.~~
3. (Currently Amended) A ~~pharmaceutical~~ unit dosage form tablet or capsule
composition according to ~~Claim 2~~ Claim 1, wherein said ~~coating~~ release-controlling agent has
a pH dissolution point of from about 6.5 to about 7.2.

4. (Cancelled) A pharmaceutical composition according to Claim 1, wherein said interactive agent component comprises calcium or phosphate.

5. (Cancelled) ~~A pharmaceutical composition according to Claim 1, wherein the ratio of said calcium component to said magnesium component is from 1:5 to 5:1.~~

6. (Currently Amended) A ~~pharmaceutical~~ unit dosage form tablet or capsule composition according to ~~Claim 5~~ Claim 1, wherein the ratio of said calcium component to said magnesium component is from 2:1 to 3:1.

7. (Currently Amended) A ~~pharmaceutical~~ unit dosage form tablet or capsule composition according to ~~Claim 2~~ Claim 1, wherein said enteric coating is applied by contacting said magnesium component with an aqueous suspension or an organic solvent.

8. (Currently Amended) A ~~pharmaceutical~~ unit dosage form tablet or capsule composition according to ~~Claim 2~~ Claim 1, wherein said enteric coating is selected from the group consisting of hydroxypropyl methylcellulose phthalate ("HPMCP") and a methacrylic acid copolymer.

9. (Currently Amended) A ~~pharmaceutical~~ unit dosage form tablet or capsule composition according to Claim 7, wherein said aqueous suspension is polyvinylacetate phthalate or cellulose acetate phthalate or a mixture thereof in combination with a plasticizing agent.

10. (Currently Amended) A ~~pharmaceutical~~ unit dosage form tablet or capsule composition according to Claim 1, wherein said magnesium component of said composition is one of a core, a layer or granules, ~~and wherein said release-controlling agent is an enteric coating having a pH dissolution point of from about 6.5 to about 7.2.~~

11. (Currently Amended) A ~~pharmaceutical~~ unit dosage form tablet or capsule composition according to Claim 10, wherein said one or more magnesium compounds is selected from the group consisting of magnesium citrate, magnesium gluconate, magnesium oxide, magnesium carbonate, magnesium hydroxide, magnesium sulfate, magnesium phosphate, magnesium aspartate and combinations thereof.

12. (Currently Amended) A ~~pharmaceutical~~ unit dosage form tablet or capsule composition according to ~~Claim 11~~ Claim 1, wherein said composition is ~~in a unit dosage form~~ selected from the group consisting of a direct compression tablet, a hard shell capsule, a layered tablet or a dry coated tablet.

13. (Currently Amended) A ~~pharmaceutical~~ unit dosage form tablet or capsule composition according to Claim 1, wherein said one or more calcium compounds is calcium carbonate, calcium citrate, calcium propionate, calcium gluconate, calcium sulfate, calcium ascorbate or combinations thereof.

14. (Currently Amended) A ~~pharmaceutical composition~~ unit dosage form tablet or capsule composition for oral administration comprising:

a) a an enteric coated magnesium component having an active ingredient consisting essentially of one or more magnesium compounds selected from the group consisting of is magnesium citrate, magnesium gluconate, magnesium oxide, magnesium carbonate, magnesium hydroxide, magnesium sulfate, magnesium phosphate, magnesium aspartate and combinations thereof, wherein said magnesium component has a pH sensitive enteric polymer coating having a pH dissolution point of from about 6.5 to about 7.2 5 to about 8; and

b) a an uncoated calcium component having an active ingredient consisting essentially of one or more calcium compounds selected from the group consisting of calcium carbonate, calcium citrate, calcium propionate, calcium gluconate, calcium sulfate, calcium ascorbate and combinations thereof;

wherein the ratio of said calcium component to said magnesium component is from 1:5 to 5:1.

15. (Currently Amended) A method for delivering to a host magnesium and calcium, said method comprising:

ingesting a ~~pharmaceutical composition~~ unit dosage form tablet or capsule composition comprising:

a) a an enteric coated magnesium component having an active ingredient consisting essentially of one or more magnesium compounds selected from the group consisting of magnesium citrate, magnesium gluconate, magnesium oxide, magnesium

carbonate, magnesium hydroxide, magnesium sulfate, magnesium phosphate, magnesium aspartate and combinations thereof, wherein said enteric coating is magnesium component has a pH sensitive enteric polymer coating having a pH dissolution point of from about 6.5 to about 7.2 5 to about 8; and

b) a an uncoated calcium component having an active ingredient consisting essentially of one or more calcium compounds;

wherein substantially all of said calcium component is released before passage into said intestine of said host and substantially all of said magnesium component is released after passage out of the stomach and into the intestine of the host, and wherein the ratio of said calcium component to said magnesium component is from 1:5 to 5:1.

16. (Cancelled) A method for delivering to a host magnesium and an interactive agent according to Claim 15, wherein said interactive agent component comprises calcium or phosphate.

17. (Currently Amended) A method for delivering to a host magnesium and calcium according to Claim 15, wherein the ratio of said calcium component to said magnesium component is from ~~1:5 to 5:1~~ 2:1 to 3:1.

18. (Previously Presented) A method for delivering to a host magnesium and calcium according to Claim 15, wherein said one or more calcium compounds is calcium carbonate, calcium citrate, calcium propionate, calcium gluconate, calcium sulfate, or calcium ascorbate or combinations thereof.